Aiqin Gu

1.4k total citations
65 papers, 1.0k citations indexed

About

Aiqin Gu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Aiqin Gu has authored 65 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Aiqin Gu's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (16 papers) and Lung Cancer Research Studies (16 papers). Aiqin Gu is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (16 papers) and Lung Cancer Research Studies (16 papers). Aiqin Gu collaborates with scholars based in China, United States and Sweden. Aiqin Gu's co-authors include Baohui Han, Huimin Wang, Wenyi Chen, Dongwen Lv, Chunlei Shi, Ming Yao, Hechun Lin, Mingxia Yan, Pengchao Hao and Jing Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of Agricultural and Food Chemistry.

In The Last Decade

Aiqin Gu

61 papers receiving 997 citations

Peers

Aiqin Gu
Li Yan China
Jun Qian China
Jia Zhong China
Qian Feng China
Etel Rodrigues Pereira Gimba Brazil
Yu Bai China
Guangmin Xi China
Jin Zhao China
Xue Chen China
Lei Zeng China
Li Yan China
Aiqin Gu
Citations per year, relative to Aiqin Gu Aiqin Gu (= 1×) peers Li Yan

Countries citing papers authored by Aiqin Gu

Since Specialization
Citations

This map shows the geographic impact of Aiqin Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aiqin Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aiqin Gu more than expected).

Fields of papers citing papers by Aiqin Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aiqin Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aiqin Gu. The network helps show where Aiqin Gu may publish in the future.

Co-authorship network of co-authors of Aiqin Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Aiqin Gu. A scholar is included among the top collaborators of Aiqin Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aiqin Gu. Aiqin Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Ying, et al.. (2024). B cells enhance EphA2 chimeric antigen receptor T cells cytotoxicity against glioblastoma via improving persistence. Human Immunology. 85(6). 111093–111093. 2 indexed citations
2.
Gu, Aiqin, Can Zhang, Chang Xu, et al.. (2023). IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy. Cancer Immunology Immunotherapy. 72(7). 2393–2403. 9 indexed citations
3.
Guo, Ting, Lei Zhang, Aiqin Gu, et al.. (2023). The Infection of Healthcare Workers and the Reinfection of Patients by Omicron Variant — Jiangsu Province, China, December 2022 to January 2023. China CDC Weekly. 5(18). 402–406. 6 indexed citations
4.
Ye, Xuanting, Yan Zhou, Yanbin Kuang, et al.. (2023). Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study. Journal of Thoracic Disease. 15(4). 2003–2011.
5.
6.
Han, Baohui, Bo Yan, Aiqin Gu, et al.. (2021). 1238P AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients. Annals of Oncology. 32. S977–S977. 2 indexed citations
7.
8.
Han, Baohui, Tianqing Chu, X. Zhang, et al.. (2019). P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 14(10). S398–S398. 5 indexed citations
9.
Yu, Xiaolu, et al.. (2018). Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR. Translational Cancer Research. 7(3). 600–608. 2 indexed citations
10.
Wang, Huimin, Yanwei Zhang, Jiajun Teng, et al.. (2017). P1.03-062 Lung Cancer Screening with Low-Dose CT in China: Study Design and Baseline Results from the First Round Screening Arm. Journal of Thoracic Oncology. 12(1). S581–S582. 2 indexed citations
11.
Wang, Huimin, et al.. (2015). Upregulated lncRNA-UCA1 contributes to progression of lung cancer and is closely related to clinical diagnosis as a predictive biomarker in plasma.. PubMed Central. 8(7). 11824–30. 97 indexed citations
12.
Gu, Aiqin, Jianhong Lu, Weimin Wang, et al.. (2015). Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer. The International Journal of Biochemistry & Cell Biology. 70. 118–125. 36 indexed citations
13.
14.
Lv, Dongwen, Xin Li, Ming Zhang, et al.. (2014). Large-scale phosphoproteome analysis in seedling leaves of Brachypodium distachyon L.. BMC Genomics. 15(1). 375–375. 33 indexed citations
15.
Hu, Xingsheng, Baohui Han, Aiqin Gu, et al.. (2014). A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Lung Cancer. 86(2). 207–212. 31 indexed citations
16.
Li, Rong, Yuqing Lou, Yanwei Zhang, et al.. (2013). Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations. Thoracic Cancer. 4(4). 433–439. 1 indexed citations
17.
Gao, Zhiqiang, Baohui Han, Huimin Wang, et al.. (2012). Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC. Oncology Letters. 3(5). 1064–1068. 5 indexed citations
18.
19.
Gao, Zhiqiang, et al.. (2011). Relations between RRM1 Protein Expression Levels and Effects of Gemcitabine and Cisplatin Chemotherapy in Advanced Non-small Cell Lung Cancer Patients. SHILAP Revista de lepidopterología. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Li Yan Breakdown of academic impact, for papers by Jun Qian Breakdown of academic impact, for papers by Jia Zhong Breakdown of academic impact, for papers by Qian Feng Breakdown of academic impact, for papers by Etel Rodrigues Pereira Gimba Breakdown of academic impact, for papers by Yu Bai Breakdown of academic impact, for papers by Guangmin Xi Breakdown of academic impact, for papers by Jin Zhao Breakdown of academic impact, for papers by Xue Chen Breakdown of academic impact, for papers by Lei Zeng
Rankless by CCL
2026